Patents Examined by Dennis Heyer
  • Patent number: 10806722
    Abstract: The subject invention describes a method of use of Ropiniroleā„¢ to alleviate and control menopausal symptoms in women, and in particular, hot flashes. The invention describes the use of Ropinirole as a dopamine agonist with affinity for the dopamine D2, D3, or D4 receptors. Ropinirole may also be used to treat menopausal symptoms in conjunction with Tizanidineā„¢ to further reduce the effects menopausal symptoms by providing a sedative and muscle relaxant effect which aids in sleep. The combination of Ropinirole and Tizanidine provides a useful new compound for treatment of menopausal symptoms that are most disruptive to the functioning in activities of daily living.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 20, 2020
    Inventor: Robert L. Knobler
  • Patent number: 10806709
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: October 20, 2020
    Assignee: G2B Pharma, Inc.
    Inventor: Nigel Ten Fleming
  • Patent number: 10799588
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: October 13, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10792304
    Abstract: Methods and compositions for the treatment, amelioration, or prevention of cancer and/or cancer metastasis by delivery of a hemodynamics altering agent such as a drag reducing polymer (DRP).
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: October 6, 2020
    Assignees: UNM Rainforest Innovations, University of Pittsburgh
    Inventors: Marina V. Kameneva, Denis Bragin, Edwin Nemoto, Richard Simmons
  • Patent number: 10787410
    Abstract: Described are methods of treating or preventing a disease in a subject treatable by modulating cell mechanics.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: September 29, 2020
    Assignee: The Johns Hopkins University
    Inventors: Douglas Robinson, Alexandra Surcel, Win Pin Ng, Caren L. Freel Meyers
  • Patent number: 10780166
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: September 22, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10780098
    Abstract: Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: September 22, 2020
    Assignee: ALLERGAN, INC.
    Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani, Andrea S. Kim, Mayssa Attar, Ronald Bradford, Rhett M. Schiffman
  • Patent number: 10780165
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: September 22, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10772851
    Abstract: Various embodiments disclosed relate to treatment of fungal infections. The present invention provides a method of treating a fungal infection including contacting a fungus including a ?-glucan that is at least partially masked from immune system detection with a therapeutically effective amount of a compound that at least partially unmasks the ?-glucan to increase immunogenicity of the fungus.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 15, 2020
    Inventors: Aaron Kurt Neumann, Harry Craig Pappas, Matthew Graus, David G. Whitten, Kirk S. Schanze, Rina Sylejmani
  • Patent number: 10772853
    Abstract: The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C15-C25) hydroxyalkanoic acid), an antioxidant, and water.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: September 15, 2020
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Drazen Ostovic, Gary Fred Musso
  • Patent number: 10765649
    Abstract: The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C15-C25) hydroxyalkanoic acid), an antioxidant, and water.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: September 8, 2020
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Drazen Ostovic, Gary Fred Musso
  • Patent number: 10758518
    Abstract: The present invention provides methods of treating hematological disorders and solid malignant tumors, using substituted indazole compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and BCL-2 kinases.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: September 1, 2020
    Assignee: Curis, Inc.
    Inventor: Robert Booher
  • Patent number: 10758543
    Abstract: This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: September 1, 2020
    Assignee: INCYTE CORPORATION
    Inventors: Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
  • Patent number: 10758617
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: September 1, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10758507
    Abstract: The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: September 1, 2020
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Sadasivan Vidyasagar, Paul Okunieff
  • Patent number: 10758618
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: September 1, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10744132
    Abstract: An injectable pharmaceutical composition includes a solution of 3-acyl-buprenorphine, or a pharmaceutically acceptable salt thereof, in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a steady release profile lasting over one week when injected into a patient. The acyl group is an alkylcarbonyl group, and an alkyl portion of the alkylcarbonyl group is a straight-chain, branched-chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl acetate, ethanol, butanol, 2-butanol, isobutanol, ispropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N,N-dimethylacetamide, propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: August 18, 2020
    Assignee: Alar Pharmaceuticals, Inc.
    Inventors: Tong-Ho Lin, Yung-Shun Wen, Jui-Wei Liang
  • Patent number: 10744198
    Abstract: Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites).
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 18, 2020
    Assignee: Najit Technologies, Inc.
    Inventors: Ian J. Amanna, Elizabeth A. Poore
  • Patent number: 10744115
    Abstract: The present invention relates, in certain embodiments, to methods for preventing and/or treating neurodegenerative damage (e.g., secondary cascade of neurodegenerative damage) and improving functional outcomes (e.g., outcomes associated with cognitive, behavior and sensorimotor function) caused by traumatic brain injury using neuroprotective lipoyl compounds. The present invention also provides, in various embodiments, compositions for use in treating and/or preventing TBI in a subject in need thereof, compounds for use in the manufacture of a medicament for treating and/or preventing TBI in a subject in need thereof, and methods of preparing a pharmaceutical composition for treating and/or preventing secondary brain damage caused by TBI.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: August 18, 2020
    Assignee: Ischemix LLC
    Inventors: Alexander Baguisi, Reinier Beeuwkes, Ralph Casale, David A. DeWahl, Jr., Steven A. Kates, Alan S. Lader
  • Patent number: 10729671
    Abstract: The invention provides complexes of Zn2+ of formulae (la) and (IIa) that are useful for treating cancer, as well as compositions and kits comprising such complexes.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: August 4, 2020
    Assignees: Rutgers, the State University of New Jersey, The Research Foundation for the State University of New York
    Inventors: David J. Augeri, Anthony F. Bencivenga, Adam Blanden, Darren R. Carpizo, John A. Gilleran, Spencer David Kimball, Stewart N. Loh, Xin Yu